A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer

NCT06760364 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Advanced Pancreatic Cancers

Interventions

DRUG: CHT102

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Collaborators

[object Object]